MB310 in Active, Mild-to-Moderate Ulcerative Colitis

Phase 1, randomised, double-blind trial in ulcerative colitis (UC) comparing Vancomycin preconditioning followed by MB310 with Vancomycin preconditioning followed by Placebo (2 arms). Primary endpoints: Incidence and causality of adverse events at 12 weeks, Incidence of treatment-emergent clinically significant changes in laboratory parameters at 12 weeks and 1 more. Started Sep 2024; status: completed.